News

The company’s flagship product is Reti-CVD, an AI diagnostic solution that autonomously assesses future cardiovascular disease risk using a retina scan.

The e-poster came in 2nd place for the August Deutman award at the EURETINA Congress

The NIH-supported findings could pave the way for genetic testing, clinical trials, and therapy development for these diseases.

Ali Erginay, MD, spoke about the important developments in retinal imaging, specifically the Red-Blue-Green (RGB) imaging modalities during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

The retina space continues to see new advancements and clinical trial results, many of which are shared at industry conferences throughout the year.

David Eichenbaum, MD, spoke with Modern Retina to provide and overview on his presentation at ASRS 2024 and the current state of geographic atrophy treatment.

Dilsher Dhoot, MD, sat down with Modern Retina to provide some insights on the phase 1 HELIOS trial, which he presented on during the 2024 ASRS meeting held in Stockholm, Sweden earlier in 2024.

Digital exclusive article on red-blue-green ultrawidefield (UWF) imaging

Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Prof Bodaghi praises the ingenuity at this year's EURETINA Innovation Spotlight (EIS)

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

The general secretary of the European Society of Retina Specialists (EURETINA) says the future of AI is here

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1.

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

Dvey-Aharon is an internationally known AI expert and the inventor of AEYE-DS.

Stefano Mercuri, MD, speaks about his team's August Deutman award-winning research on retinitis pigmentosa and Rho gene mutations

Alexandra Miere, MD, PhD, says oculomics is the next big thing in eye care.

Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina clinicians connecting at meetings around the globe.

Clare Bailey, MD, shared data from the multi-country study on faricimab for patients with DME and nAMD

Inflammasome Therapeutics has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug, K9.

How retinal imaging can provide clinicians a deeper understanding of myopia

New research and EURETINA highlights from the director of the "underdog" eye clinic

Nicole Eter, MD, discussed the use of a magnification implant being used in patients with geographic atrophy (GA) at from this year's EURETINA congress being held in Barcelona, Spain, which took place September 19-22, 2024.